Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naive Subjects With Genotype 1 Hepatitis C.

Next Previous
Trial Profile

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naive Subjects With Genotype 1 Hepatitis C.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation

Most Recent Events

  • 07 Mar 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
  • 07 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 28 Jan 2011 According to a Mitsubishi Tanabe Pharma Corporation, an application for the manufacturing and marketing approval of telaprevir for chronic hepatitis C has been submitted in Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top